2007年毕业于浙江大学药学院，获得学士学位。同年于协和医学院医药生物技术研究所攻读博士学位，2012年毕业后一直任职于药物研究所。主要从事抗肿瘤药物的机制研究和小分子抗肿瘤药物的研发，包括IDO, PD-1/PD-L1，KRAS，CDK8和PI3K/HADC等等。发表SCI一作文章10余篇；参与申请国内外专利20余项，获得授权专利8项。主持和参与多项科研项目，包括：国家自然科学基金青年项目、药物所基本科研业务费、十三五创新药物重大科技专项、创新工程重大协同创新项目和国家自然科学基金面上项目等。
肿瘤药理，肿瘤免疫，抗肿瘤药物研发
1. C. Zhou1, F. Lai1, Sheng, X. Chen, Y. Li, Z. Feng, Design, Synthesis and Biological Evaluation of Phenyl Urea Derivatives as IDO1 Inhibitors, Molecules, 25 (2020).
2. Y. Zang1, F. Lai1, J. Fu, C. Li, J. Ma, C. Chen, K. Liu, T. Zhang, X. Chen, D. Zhang, Novel nitric oxide-releasing derivatives of triptolide as antitumor and anti-inflammatory agents: Design, synthesis, biological evaluation, and nitric oxide release studies, Eur J Med Chem, 190 (2020) 112079.
3. G. Cui1, F. Lai1, X. Wang, X. Chen, B. Xu, Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors, Eur J Med Chem, 188 (2020) 111985.
4. K. Zhang1, F. Lai1, S. Lin, M. Ji, J. Zhang, Y. Zhang, J. Jin, R. Fu, D. Wu, H. Tian, N. Xue, L. Sheng, X. Zou, Y. Li, X. Chen, H. Xu, Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases, J Med Chem, 62 (2019) 6992-7014.
5. N. Xue1, F. Lai1, T. Du, M. Ji, D. Liu, C. Yan, S. Zhang, X. Yu, J. Jin, X. Chen, Chaperone-mediated autophagy degradation of IGF-1Rbeta induced by NVP-AUY922 in pancreatic cancer, Cell Mol Life Sci, 76 (2019) 3433-3447.
6. J. Jin1, M. Ji, R. Fu, M. Wang, N. Xue, Q. Xiao, J. Hu, X. Wang, F. Lai*, D. Yin*, X. Chen*, Sphingosine-1-Phosphate Receptor Subtype 1 (S1P1) Modulator IMMH001 Regulates Adjuvant- and Collagen-Induced Arthritis, Front Pharmacol, 10 (2019) 1085.
7. Q. Zhang1, S. Xu1, F. Lai1, Y. Wang, N. Zhang, M. Nazare, H.Y. Hu, Rapid Synthesis of gamma-Halide/Pseudohalide-Substituted Cyanine Sensors with Programmed Generation of Singlet Oxygen, Org Lett, 21 (2019) 2121-2125.
8. Y. He1, J. Wen, Q. Cui, F. Lai*, D. Yin*, H. Cui*, Quantitative Evaluation of in Vivo Target Efficacy of Anti-tumor Agents via an Immunofluorescence and EdU Labeling Strategy, Front Pharmacol, 9 (2018) 812.
9. F. Lai1, Z. Shen1, H. Wen, J. Chen, X. Zhang, P. Lin, D. Yin, H. Cui, X. Chen, A Morphological identification cell cytotoxicity assay using cytoplasm-localized fluorescent probe (CLFP) to distinguish living and dead cells, Biochem Biophys Res Commun, 482 (2017) 257-263.
10. F. Lai1, Q. Liu1, X. Liu, M. Ji, P. Xie, X. Chen, LXY6090 - a novel manassantin A derivative - limits breast cancer growth through hypoxia-inducible factor-1 inhibition, Onco Targets Ther, 9 (2016) 3829-3840.
11. F. Lai1, N. Madan, Q1. Ye, Q. Duan, Z. Li, S. Wang, S. Si, Z. Xie, Identification of a mutant alpha1 Na/K-ATPase that pumps but is defective in signal transduction, J Biol Chem, 288 (2013) 13295-13304.
12. Q. Ye1, F. Lai1, M. Banerjee, Q. Duan, Z. Li, S. Si, Z. Xie, Expression of mutant alpha1 Na/K-ATPase defective in conformational transition attenuates Src-mediated signal transduction, J Biol Chem, 288 (2013) 5803-5814.
13. Y. Xu1, F. Lai1, Y. Xu, Y. Wu, Q. Liu, N. Li, Y. Wei, T. Feng, Z. Zheng, W. Jiang, L. Yu, B. Hong, S. Si, Mycophenolic acid induces ATP-binding cassette transporter A1 (ABCA1) expression through the PPARgamma-LXRalpha-ABCA1 pathway, Biochem Biophys Res Commun, 414 (2011) 779-782.
1.《中国药用植物志》艾铁民主编，中国科学出版社，2016年
2.《中华医学百科全书 肿瘤学（五）》，石远凯、刘德培主编，中国协和医科大学出版社，2020年
1. 苄苯醚类衍生物、及其制法和药物组合物与用途。冯志强,陈晓光,杨阳,来芳芳,季鸣,张莉婧,郑义,薛妮娜,王克,李凌。申请日期：2017.05.23. 授权日期：2021.03.09（美国）。
2. 烟醇醚类衍生物、及其制法和药物组合物与用途。冯志强,陈晓光,杨阳,郑义,来芳芳,季鸣,周川,张莉婧,王克,薛妮娜,李凌。申请日期：2017.05.23. 授权日期：2020.11.03（俄罗斯）. 授权日期：2021.04.13（美国）。
3. 溴代苄醚衍生物、及其制法和药物组合物与用途。冯志强,陈晓光,张莉婧,杨阳,来芳芳,季鸣,周川,郑义,薛妮娜,李凌。申请日期：2017.05.23。
4. 苯醚类衍生物、及其制法和药物组合物与用途。冯志强,陈晓光,杨阳,周川,来芳芳,季鸣,金小锋,薛妮娜,郑义,陈浩,李凌。申请日期：2017.05.23. 授权日期：2021.01.05（美国）。
5. 苄苯醚类衍生物、及其制法和药物组合物与用途。冯志强,陈晓光,杨阳,来芳芳,季鸣,张莉婧,郑义,薛妮娜,王克,李凌。申请日期：2017.05.23。
6. 烟醇醚类衍生物、及其制法和药物组合物与用途。冯志强,陈晓光,杨阳,郑义,来芳芳,季鸣,周川,张莉婧,王克,薛妮娜,李凌。申请日期：2017.05.23。
1.2020年，“梁周黄于刘青年科技奖”-三等奖，药物所
